Expert Insights: Current and Future Directions in Chronic and Acute Leukemias
Release Date: October 15, 2019
Watch the experts who are actively engaged in the care of patients with chronic and acute leukemias discuss current practices and provide up-to-date information on how best to care for your patients with leukemia. Faculty will discuss treatment strategies for patients with chronic myeloid leukemia (CML), with a focus on moving next-generation tyrosine kinase inhibitors (TKIs) into earlier lines of therapy. Additionally, they will examine how to best manage patients with relapsed/refractory acute lymphoblastic leukemia (ALL). And finally, they will discuss strategies for selecting therapeutic approaches for patients with newly diagnosed acute myeloid leukemia (AML).
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with leukemia.
- Evaluate clinical data for various TKI-based therapies in patients with CML, including newly diagnosed patients and those in later lines of therapy
- Assess various treatment strategies for patients with relapsed/refractory ALL, in consideration of salvage status, MRD, and cytogenetics
- Compare and contrast therapeutic approaches for newly diagnosed patients with AML, including patients who are both eligible and ineligible for intensive induction chemotherapy
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Materials will be available online through October 15, 2020
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Conference Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All conference faculty and planning committee members have no conflicts to disclose with the exceptions listed below:
All disclosed conflicts of interest have been resolved by independent content review.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
Elias Jabbour, MD - Moderator
Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Grants/Research Support, Consultant: AbbVie Inc., Bristol-Myers Squibb Company, Pfizer Inc., Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited
Susan O’Brien, MD
Associate Director for Clinical Services, Chao Family Comprehensive Cancer Center
University of California
Irvine Medical Center
Consultant: Alexion, Amgen Inc., Aptose Biosciences Inc., Astellas Pharma US, Inc., Celgene Corporation, Eisai Co., Ltd., GlaxoSmithKline, Janssen Oncology, AbbVie Inc., Vaniam Group LLC, Verastem
Research Support: Acerta Pharma, Kite Pharma, Regeneron Pharmaceuticals
Consultant/Research Support: Gilead Sciences, Inc., Pharmacyclics LLC, TG Therapeutics, Pfizer Inc., Sunesis Pharmaceuticals, Inc.
Educational support provided by Pfizer Inc.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.